BPC-157 is the most under-discussed thing on this board
Thinking out loud about this: BPC-157 is the most under-discussed thing on this board. The three questions, kept separate, because this board runs them together constantly. Identity : is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity : how much peptide is in the vial?…
The evidence base, described honestly, which almost no summary of it does.
The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.
That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.
Sent a vial to Janoshik: 99.4% against a claimed 98.5%, with the mass confirming the sequence. Both halves mattered to me.
What method produced that purity number?
Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.
Disagree — that is a rodent study and you are stating it as a human effect. The distance between those is the entire argument.